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Summary.-Inbred rats were injected s.c. with cells of syngeneic hepatoma D23,
D23 cells + BCG as a mixed inoculum, mixed inoculum one side and D23 alone
contralaterally, or BCG alone. Their blood mononuclear cells were tested weekly
for cytotoxicity against D23 target cells using a microcytotoxicity method and their
serum was tested for blocking activity against cytotoxicity by lymph node cells from
immunized rats.
Tumour growth was suppressed when BCG was in contact with tumour cells
but tumours grew unhindered if the BCG was given contralaterally. All rats
receiving tumour cells, either alone or mixed with BCG, developed cell-mediated
cytotoxicity which remained until termination at 35 days. Rats receiving BCG
alone showed slight initial cytotoxicity which disappeared after 7 days. Blocking
factors appeared in the serum of rats which developed growing tumours but not
in rats whose tumours were suppressed by contact with BCG. Splenectomized
rats did not differ markedly from intact rats in the in vitro studies or in vivo.
It is concluded that development of cell-mediated immunity and blocking factors
depends more upon treatment with tumour cells and the subsequent behaviour
of the tumour than upon treatment with BCG per se.
IT is now well established that Bacillus
Calmette Guerin (BCG) has marked anti-
tumour properties, as demonstrated by
studies with a wide variety ofexperimental
tumours (Baldwin and Pimm, 1971, 1974;
Bartlett, Zbar and Rapp, 1972; Chassoux
and Salomon, 1975; Moore, Lawrence
and Nisbet, 1975; Simmons, Rios and
Kersey, 1972). It has been recognized that
close contact between tumour cells and
BCG often produces better tumour sup-
pression than administration of the BCG
at a site distant from the tumour cells,
and this effect has been attributed largely
to the host response to BCG itself rather
than the tumour cells (Bartlett et al.,
1972; Moore et al., 1975). However,
there is no doubt that an immune response
to tumour cells also develops as a result
of BCG-induced growth suppression, since
rats which have rejected immunogenic
tumours as a result of BCG treatment
are resistant to further challenge with the
same tumour (Baldwin and Pimm, 1973).
Analysis of the tumour-immune re-
sponse in BCG-treated animals can most
conveniently be carried out by means
of in vitro tests. Bansal and Sjogren
(1973) have shown that a polyoma-virus-
induced rat tumour could be inhibited
if BCG was administered at the time
of tumour grafting, and that treated
animals developed an increased cell-
mediated immunity to the tumour demon-
strable by a microcytotoxicity test. If,
however, BCG was given after the ap-
pearance of a palpable tumour nodule,
tumour growth was accelerated. This
was accompanied by an increase in serum
factors which " blocked " cell-mediated
immunity, but there was no increase in
direct cell-mediated immunity.EFFECT OF BCG ON TUMOUR-IMMUNE RESPONSE
The following report is a study of
the development of cell-mediated cyto-
toxicity and humoral blocking or inhibi-
tory factors in rats treated with cells
of an aminoazo-dye-induced hepatoma
(D23) and BCG. This tumour can be
suppressed by admixture of viable cells
with BCG (Baldwin and Pimm, 1973)
and its immunological behaviour has
been well studied by in vitro cytotoxicity
methods (Baldwin, Embleton and Robins,
1973; Baldwin, Price and Robins, 1973).
It was thus possible to set up experimental
groups with a fairly predictable course
of tumour development and to evaluate
the immune response of individual rats
over a period of time in order to attempt
correlations between the host anti-tumour
response and the behaviour of the tumour
in response to BCG treatment.
MATERIALS AND METHODS
Animals.-Inbred Wistar rats were used.
These rats accept skin grafts between
individuals of the same sex and strain.
Tumours.-The tumour mainly used in
these studies was a moderately immunogenic
Wistar rat hepatoma, D23, originally induced
by oral administration of 4-dimethylamino-
azobenzene and maintained by serial s.c.
transplantation in syngeneic male rats. Cell
suspensions for use in vivo were prepared
by trypsinization of solid tumour tissue,
suspensions consisting of more than 90%
viable cells being obtained.
A cell line was maintained in monolayer
culture inglass bottlesusing Eagle'sMinimum
Essential Medium (MEM) supplemented with
calf serum (10%) penicillin (100 iu/ml) and
streptomycin (200 tg/ml). This line was
initiated from transplanted tumour tissue
and was used as a source of target cells for
in vitro microcytotoxicity assays. The cul-
tured cells were harvested with 0 25%
trypsin and always consisted of 100% viable
single cell suspensions. For specificity tests,
monolayer cultures of two 3-methylchol-
anthrene-induced sarcomas, Mc7 and Mc57,
were also used.
BCG.-Dried percutaneous BCG vaccine
was supplied by Glaxo Laboratories Ltd.,
Greenford, Middlesex. This was reconsti-
tuted with distilled water (0 3 ml per am-
poule) immediately before use.
Immunization.-Groups of animals were
treated by one ofthe following protocols:
(a) 5 X 104 viable D23 cells given s.c. in
the right flank.
(b) 1 mg BCG s.c. in the left flank.
(c) 5 x 104 viable D23 cells + 1 mg BCG
mixed and given s.c. in the left
flank.
(d) 5 x 104 D23 cells + 1 mg BCG mixed
in the left flank and 5 X 104 D23
cells alone in the right flank.
(e) 5 X 104 D23 cells + 1 mg BCG mixed
intheleftflank and 5 x 104irradiated
(15,000 R) D23 cells in the right
flank.
(f) Mock splenectomy followed by 5 X 104
viable D23 cells in the right flank.
(g) Splenectomy followed by 5 x 104
viable D23 cells in the right flank.
(h) Splenectomy followed by 5 X 104
D23 cells + 1 mg BCG mixed in the
left flank and 5 X 104 viable D23
cells in the right flank.
Mixtures of D23 cells and BCG were
prepared immediately before injection.
Microcytotoxicity tests.-Cultured D23
cells were plated at 200/well in Cooke
M29 ART Microtitre plates usingMEM-+10%
calf serum. The cells were incubated for
between 4 and 24 h to allow them to attach
to the bottom ofthe wells.
Blood mononuclear cells were prepared
from individual treated and control rats
at weekly intervals until tumour sizes (in
groups which developed growing tumours)
necessitated termination of the experiments
(4-5 weeks after initial treatment). Effector
cells from this source were used because this
allowed repeated testing of individual rats.
Heparinized blood (2 ml) obtained by cardiac
puncture was layered on to 2 ml of a mixture
of Ficoll (6.35% w/v) and Triosil (13.4% v/v)
in a 7 ml disposable plastic bijou. The
blood was centrifuged at 400 g for 20 min
and the supernatant plasma was removed
and stored at -20°C for serum blocking
factor assay. The mononuclear cell band
at the interface between plasma and Ficoll-
Triosil was collected and the cells washed
twice in MEM before being adjusted to a
final concentration of 5 x 105/ml. Giemsa-
stained smears showed the granulocyte con-
tamination to be less than 2%. Medium
was removed from the plated D23 target
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cells and replaced by mononuclear cells
at 105/well in 0-2 ml of medium. After
45 min incubation at 37TC the wells were
supplemented with calf serum to a final
concentration of 10%. Mononuclear cells
from untreated control rats were tested at
the same time as those from treated rats
and 8 wells were used for each cell prepara-
tion. The plates were incubated for 2 days
at 3700 and then gently rinsed with saline
to remove all non-adherent cells. The
remaining tumour cells were fixed with
methanol, stained with Giemsa and counted
under x 30 stereoscopic magnification. Per-
centage cytotoxicity was calculated by the
formula:
% cytotoxicity =
Mean No. of cells Mean No. of cells
in wells exposed to in wells exposed to
control mononuc- test mononuclear
100 x - lear cells cells Mean No. of cells in wells exposed to
control mononuclear cells
Blocking factor assay.-D23 target cells
were plated at 200/well and allowed to
attach to the bottom of the wells. Lymph
node cells (LNC) were prepared from control
rats or rats immunized with 15,000 R
-irradiated grafts of hepatoma D23, as pre-
viously described (Baldwin et al., 1973a).
These lymph node cells have been shown to
react specifically against the immunizing
tumour (Baldwin et al., 1973a; Zoller,
Dickinson and Embleton, 1975), and were
therefore used to provide an effector cell
preparation as near standard as possible.
Blood plasma was isolated from the super-
natant during the preparation ofmononuclear
cells from heparinized blood. Plasma from
treated or control rats was diluted 1/5 in
MEM and 0-05 ml aliquots were added to
the target cells after removal of the super-
natant medium. The cells were incubated
for 45 min at 370C and 2 x 105LNC were
added in 0-2 ml MEM without removing the
plasma. After a further 45 min calf
serum was added to a concentration of
10% and the plates were incubated for
2 days at 370C. Percentage blocking was
calculated by comparing the % cytotoxicity
of immune LNC in the presence of test
plasma with % cytotoxicity in the presence
of control plasma as described previously
(Baldwin et al., 1973a).
RESULTS
Growth of D23 hepatoma cells was
suppressed in all rats receiving a mixed
inoculum of 5 X 104 tumour cells and
1 mg BCG, while the same dose of tumour
cells alone grew progressively (Table I,
Fig. 1). In animals receiving a mixed
inoculum of tumour cells and BCG on
one side and a simultaneous contra-
lateral inoculum of D23 cells only, the
contralateral inoculum grew more slowly
than in rats not treated with BCG
(Fig. 1), but complete suppression was
only observed in 1/11 animals (Table I).
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Fie. 1.-Effect of BCG on growth of rat
hepatoma D23 locally and at a distant
site. BCG was administered throughout
at a dose of 1 mg/rat and D23 at 5 x 104
cells per inoculum. RHS indicates the
inoculum was given s.c. on the right flank
and LHS indicates the left flank. Vertical
bars indicate standard errors of mean
values for between 3 and 11 rats (see
Table 1).
Cell-mediated cytotoxicity against D23
cells by blood mononuclear cells was
observed on repeated occasions in all
animals treated with tumour cells, whether
or not the cells were suppressed by
admixture with BCG (Table I). Rats
developing growing tumours had cyto-
toxic cells up to 35 days after inoculation,
at which time the size of the tumours
necessitated termination of the experi-
ments (Fig. 2). In rats whose tumour
was completely suppressed by admixture
with BCG, however, cytotoxicity gradu-
ally decreased after 7 days and levels
detected after 28 days were insignificant
(Fig. 2). Another group were given cells
ORlas
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TABLE I.-Influence ofBCG on Growth of Rat Hepatoma D23 and the Development
ofTumour-directed Cell-mediated Cytotoxicity and Serum Blocking Factor
Treatment*
D23 cells only
BCG only
D23 cells + BCG mixed
D23 cells + BCG mixed, and contralateral D23 cells
D23 cells + BCG mixed, and contralateral irradiatedt D23 cells
Mock splenectomy and D23 cells
Splenectomy and D23 cells
Splenectomy, D23 cells + BCG mixed, and contralateral D23 cells
* D23 cells and BCG were injected s.c.
t Positive on at least two occasions throughout the time course.
t 15,000 R 60Co y-irradiation.
104
Time (Days)
FiP. 2.-Cell-mediated cytotoxicity against
hepatoma D23 cells by rats treated with
D23 cells and/or BOG.
inactivated by 60Co-irradiation (15,000 R)
and these showed a similar decline of
cytotoxicity after 7 days. Rats injected
only with 1 mg BCG showed a low level
of cytotoxicity at 7 days, but this was
transient and no significant cytotoxicity
was detectable at 14 days or later
(Fig. 2).
Serum blocking activity was also
demonstrable in all rats developing grow-
ing tumours (Table I), in agreement with
previous studies on hosts bearing hepa-
toma D23 (Baldwin et al., 1973a). This
was detectable at 7 days and continued
to be present up to 35 days, fairly constant
levels giving around 80% to 90% blocking
being observed throughout the time
course. Rats not developing growing
tumours did not have significant blocking
activity at any stage, although a small
so
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8/8 8/8 8/8
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3/3 3/3 3/3
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FiG. 3.-Blocking of cell-mediated cytotoxi-
city against hepatoma D23 cells byplasma
fromratstreatedwith D23 cellsand/orBCG.
insignificant degree of blocking appeared
during the first 2 weeks (Fig. 3). These
animals included those whose tumour
was inhibited by contact with BCG,
rats treated with BCG alone and the
single rat whose contralateral tumour
inoculum was suppressed by an injection
of tumour cells + BCG (Table I). Of 4
rats whose contralateral tumour was
deliberately prevented from growing by
irradiation, blocking activity was observed
in only one (Table I).
Splenectomized rats
Tumours resulting from an injection
of 5 X 104 D23 cells developed in splen-
ectomized rats at a slightly faster rate
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than in intact or sham-operated controls,
but in animals simultaneously given a
mixed inoculum of BCG and tumour
cells on the opposite flank the rate of
growth was retarded (Fig. 4), as in intact
rats (Fig. 1). Thus splenectomy had no
influence on the weak immunotherapeutic
effect of the mixed inoculum on the
contralateral tumour.
Cell-mediated cytotoxicity was not im-
paired in splenectomized rats, being about
50% at Day 7 and continuing at about
the same or a slightly increased level up
to 28 days (Fig. 5). Splenectomized
animals which had been given an inoculum
of BCG and D23 cells in addition to
contralateral tumour cells also had a
moderately high level of cytotoxic mono-
nuclear cells at 7 days, but this diminished
to a fairly low level at 21-28 days (Fig. 5).
Serum blocking activity was demon-
strable in all groups, but it developed
more slowly than in intact rats and did
not reach their value until 14 days
(Fig. 6) in splenectomized rats. Serum
blocking factor remained detectable in
E
E
.2_
E
2
;
Time (Days)
Fie. 4. Effect of BCG-tumour-cell vaccine
treatment on growth of hepatoma D23 in
splenectomized rats.
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FIG. 5.-Cell-mediated cytotoxicity against
D23 cells by splenectomized rats treated
with D23 cells + BCG.
0)
0-
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FIG. 6.-Blocking of cell-mediated cytotoxi-
city against hepatoma D23 by plasma from
splenectomized rats treated with D23 cells
+ BCG.
all animals up to 28 days, although
there was some decrease in the group
treated with mixed BCG and tumour cell
vaccine. The reduction of blocking ac-
tivity in this group appeared later than
the reduction of cytotoxicity (Fig. 5)
which was also observed.
Specificity tests
Previous studies have indicated that
cytotoxicity against rat hepatoma cells
by lymph node cells from immunized or
tumour-bearing animals is tumour-speci-
fic, with little cross-reaction between
tumours with antigens shown to be
distinct by transplantation tests (Bald-
win et al., 1973a). The specificity of
action of mononuclear cells prepared
from heparinized blood of animals bearing
tumours developing from trypsinized cell
suspensions is shown in Table II, which
lists cross-tests between hepatoma D23
and two sarcomata, Mc7 and Mc57.
These three tumours have distinct tu-
mour-rejection antigens which do not
cross-react in vivo. The data show that
blood mononuclear cells from rats bearing
hepatoma D23 are cytotoxic for D23
cells but have only an insignificantly
small effect on sarcoma cells compared
with control mononuclear cells. Cells
from sarcoma-bearing rats were reactive
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TABLE 11.-Specificity of Cytotoxicity by Blood Mononuclear Cellsfrom
Tumour-bearing Rats
Target Mononuclear*
cells cell donor
D23 Normal control
D23 tumour bearer, 21 days
Mc7 tumour bearer, 21 days
Mc57 tumour bearer, 21 days
Mc7 Normal control
D23 tumour bearer, 21 days
Mc7 tumour bearer, 21 days
Mc57 Normal control
D23 tumour bearer, 21 days
Mc7 tumour bearer, 21 days
Mc57 tumour bearer, 21 days
No. of survivingt
target cells
36±2
5±1
30±2
31±2
57±3
53±2
15±1
43±2
37±2
38±3
12±2
* Tumour-bearing donors were injected s.c. with trypsinized tumour cells which were allowed to grow
for 21 days.
t Mean number of cells per well + standard error.
against their respective tumour, but did
not significantly alter the survival of
other target cells, including D23. These
results were obtained with rats bearing
tumours for 21 days, which is beyond
the point at which the slight non-specific
activity was observed in BCG-treated
rats (Fig. 2), and show that the cell-
mediated cytotoxicity seen against D23
throughout the later part of the time
course was tumour-specific.
Serum-mediated blocking of cell-medi-
ated immunity has also previously been
reported to be specific for given tumours,
using serum prepared from clotted blood
of tumour-bearing animals (Baldwin et
al., 1973a, b). In the present study,
however, plasma was isolated from hepar-
inized blood in order to assay blocking
activity in the same samples as were used
for effector cell preparation. In order
to test whether heparin produced non-
specific effects, a further series of cross-
tests were carried out as shown in Table
III. Lymph node cells from immune
donors were used as effector cells in the
majority of the tests because these were
known to be tumour-specific in activity
(Baldwin et al., 1973a). In each test
the base-line was percentage cytotoxicity
in the presence of normal rat plasma.
Against this baseline, cytotoxicity against
D23 by immune lymph node cells was
diminished by treatment with D23 tu-
mour-bearer plasma but not by plasma
from rats bearing either sarcoma Mc7 or
Mc57. Similarly, D23 tumour-bearer
plasma did not block cytotoxicity against
Mc7 or Mc57 target cells by specifically
immune lymph node cells. Thus, block-
ing activity detectable in tumour-bearer
plasma had tumour-related specificity
which appeared to be unaffected by the
use ofheparin.
Included in Table III are tests of
plasma blocking activity against D23
tumour-bearer blood mononuclear cells.
Cytotoxicity against D23 mediated by
these cells was blocked by D23 tumour-
bearer plasma, but not by Mc7 tumour-
bearer plasma. This indicates that the
types of effector cells used to monitor
cytotoxicity in Table I (Figs. 2 and 5)
were also subject to the blocking effects
of humoral factors in tumour-bearing
animals.
DISCUSSION
The growth of hepatoma D23 could
be suppressed by admixture of tumour
cells with BCG as previously reported
(Baldwin and Pimm, 1973). Growth of
Percentage
cytotoxicity
86
(P<O 001)
17
14
6
73
(P<O 001)
14
12
71
(P<ro 001)
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TABLE III.-Specificity of Blocking of Cell-mediated Cytotoxicity by Plasma
from Tumour-bearing Rats
Target
cells
D23
Effector* cells
D23-immune LNC
D23 D23 tumour-bearer BM
Mc7 lc7-immune LNC
Plasmat donor
Normal control
D23 tumour bearer
Mc7 tumour bearer
Mc57 tumour bearer
Normal control
D23 tumour bearer
Mc7 tumour bearer
Normal control
D23 tumour bearer
Mc7 tumour bearer
Mc57 Mc57-immune LNC Normal control
D23 tumour bearei
Mc57 tumour bearer
55
(P<0O 001)
54
(P<0. 001)
6
2
89
(P<0.01)
* Immune LNC = lymph node cells from tumour-immune rats. Tumour bearer BM = blood mono-
nuclear cells from rats bearing tumours growing from trypsinized D23 cells. Similar effector cells from
normal rats were used as controls.
t Plasma was isolated from heparinized blood of rats bearing tumours growing for 21 days from s.c.
injected trypsinized cells.
a contralateral inoculum of tumour cells
alone given simultaneously, however, was
not completely suppressed but showed
retardation compared with tumour growth
in untreated control rats. Similar re-
tardation of tumour growth by a distant
inoculation of D23 cells mixed with BCG
occurred in splenectomized rats, although
the overall rate of tumour growth was
slightly accelerated in these animals
compared with equivalent groups whose
spleen was intact. Using strongly im-
munogenic polyoma-virus-induced rat tu-
mours, Bansal and Sjogren (1972, 1973)
have shown that splenectomy in their
system can lead to retardation or regres-
sion of tumours if combined with immune
serum or BCG treatment.
Cell-mediated cytotoxicity developed
in all rats treated with D23 tumour
cells, whether or not these grew pro-
gressively or were suppressed by BCG
treatment or y-irradiation. Animals with
growing tumours exhibited strong cyto-
toxicity right up to the time of termina-
tion (5 weeks), while those with sup-
pressed tumours showed a decline in
cytotoxicity after 14 days although cyto-
toxic cells were still detectable up to
28 days after inoculation. The animals
with BCG-suppressed tumours at no time
showed stronger reactivity than those
given tumour cells alone, contrary to
the findings of Bansal and Sjogren (1973)
who reported that cell-mediated cyto-
toxicity to polyoma tumours was in-
creased in BCG-treated rats.
Animals treated with BOG alone
showed a slight transient cell-mediated
cytotoxicity at 7 days, which was not
Cytotoxicity
50
(P<0O 001)
6
44
(P< 0.01)
46
(P<0 01)
52
(P<001)
10
48
(P<0.01)
51
(P< 0 001)
51
(P<0. 001)
-6
Blocking
88
(P< 0.01)
12
81
(P<0. 01)
8
0
100
(P<0.01)
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evident thereafter. This could have been
due to the presence of activated mono-
cytes in the mononuclear cell suspensions
in the early stages after treatment, since
it has been shown that BCG-primed
macrophages are cytotoxic for tumour
cells (Evans and Alexander, 1972). No
attempt had been made to separate
monocytes from lymphocytes in the pres-
ent studies, since it was felt that either
cell type might act as an effector cell
in the BCG immunotherapy model em-
ployed.
Serum factors blocking cell-mediated
cytotoxicity were assayed with the test
serum present during the whole period
of incubation of effector cells with target
cells, rather than by pretreatment of
effector cells or target cells as in previous
studies (Baldwin et al., 1973a, b). Under
these conditions, significant blocking was
found in all animals which developed
growing tumours, including both intact
and splenectomized animals. Serum from
rats bearing D23 tumour has previously
been shown to contain factors which
can block cytotoxicity when applied to
the target cells (Baldwin et al., 1973a;
Bowen, Robins and Baldwin, 1975) or
to the effector cells (Baldwin et al.,
1973b; Bowen et al., 1975). In both
situations the blocking effect has been
attributed to complexes oftumour antigen
and tumour-specific antibody, and inhibi-
tion at the effector cell level can also
be accomplished by treatment with tu-
mour antigen alone. Bansal and Sjogren
(1972, 1973) have interpreted the thera-
peutic effects of splenectomy in their
polyoma rat tumour system on the basis
of loss of blocking activity owing to the
lack of circulating complexes resulting
from reduced antibody-forming capability.
This was supported by in vitro tests
showing a loss of blocking activity in
serum when tested by pretreatment of
target cells. In the situation where
serum is present throughout the incuba-
tion, however, it is conceivable that
the blocking effect is due to inhibition
of effector cells by soluble antigen shed
39
by the tumour in the case of splenectom-
ized animals, and either by antigen or
immune complexes in intact animals.
The fact that blocking activity was
detected later in splenectomized rats than
in rats with intact spleens lends support
to the idea that different mechanisms
were operating, although the end effect
was the same in both situations.
In view of the time lag in blocking
factor detection, there was no correlation
between blocking measured in vitro and
the slightly accelerated development of
tumours in the splenectomized groups.
Neither can the growth rate be explained
on the basis of reduced cell-mediated
immunity, since cell-mediated cytotoxicity
was equally high in intact and splenectom-
ized rats. In contrast to tumour-bearing
rats, no blocking factor was detectable
in rats which failed to develop tumours.
This was not attributable to BCG treat-
ment, since BCG-treated rats which grew
contralateral tumours had considerable
blocking activity, but was correlated
only with the lack of growing tumours.
These studies were undertaken in
order to ascertain whether any differences
could be found in animals given BCG
immunotherapy and/or splenectomy com-
pared with normal tumour-bearing ani-
mals, correlated with tumour growth.
This is an important concept in relation
to current cancer immunotherapy trials
in man, where attempts are being made
to correlate the clinical course of the
disease with in vitro measurements of
tumour-directed immunity, as exemplified
by trials with malignant melanoma (Ber-
kelhammer et al., 1975; Currie, 1973;
Currie and McElwain, 1975). In the rat
hepatoma system, where only weak im-
munotherapeutic effects were obtained,
there was a strong correlation between
tumour growth and serum blocking ac-
tivity, but no correlation between BCG
treatment and blocking factor develop-
ment. Cell-mediated cytotoxicity was
comparable in all groups of tumour-
treated rats whether they received im-
munotherapy, splenectomy or no other
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treatment. The development of cyto-
toxicity was dependent only upon treat-
ment with tumour D23, and the de-
velopment ofblocking activity was depen-
dent only upon whether the tumour was
suppressed or allowed to grow. BCG
was only effective in so far that it pro-
duced suppression of tumour cells in
contact with it and splenectomy had
little effect on any of the immune para-
meters measured, so it must be concluded
that neither of these treatments affected
the in vitro measurements per se.
The author wishes to thank Mrs B. A.
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